← Back to screener

TENAX THERAPEUTICS, INC. TENX

Rank #2425 · Nasdaq · $0.0B market cap
Audited by Cherry Bekaert LLP, no going-concern flag in the latest filing.
Score
19.4
P/E
-2.7
P/B
5.86
ROE
-217.4%
Op. Margin
–%
Debt Ratio
58%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -2.7x, P/B 5.86x. Ranks in the top 81% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -217.4%. Ranks in the top 97% of the universe.

Safety ★★★★☆
Good

Debt ratio 58%. Ranks in the top 26% of the universe.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2012$0.0B$0.0B$0.0B$0.0B10238.4312
2013$0.0B$-0.0B$-0.0B$-0.0B-2259.7-120
2014$0.0B$-0.0B$-0.0B$-0.0B-435.7-1433
2015$0.0B$-0.0B$-0.0B$-0.0B-10452.1-593
2016$0.0B$-0.0B$-0.0B$-0.0B-10452.1-707
2017–$-0.1B$-0.0B$0.1B–10
2018–$-0.0B$-0.0B$0.0B–11
2019–$-0.0B$-0.0B$0.0B–18
2020–$-0.0B$-0.0B$0.0B–22
2021–$0.0B$-0.0B$0.0B–59
2022–$-0.0B$-0.0B$0.0B–38
2023–$0.0B$0.0B$0.0B–45
2024$0.0B$-0.0B$-0.0B$0.0B–240
2025$0.0B$-0.0B$-0.0B$0.0B–58

← See the full screener